Processa Pharmaceuticals Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Processa Pharmaceuticals Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- PCSA
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001533743
Board of directors
-
David Young · Director · Pres. Research & DevelopmentSince 2023
-
George K. Ng · Director · Chief Executive OfficerSince 2023
-
Geraldine Pannu · DirectorSince 2023
-
James R. Neal · DirectorSince 2023
-
Justin W. Yorke · DirectorSince 2023
-
Khoso Baluch · DirectorSince 2023
-
Virgil Thompson · DirectorSince 2023
Chief executives
David Young
· President & CEO
Dates unknown
George K. Ng
· Chief Executive Officer
Dates unknown
Board connections
5 of this board's directors also sit on 5 other boards.
- via George K. Ng
- via Justin W. Yorke
- via Khoso Baluch
- via James R. Neal
- via Geraldine Pannu
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 7, 2024 | David Young Director, Officer (Pres. Research & Development) | Open-market purchase | +21,000 | $2.45 | $51,450 |
| Feb 6, 2024 | David Young Director, Officer (Pres. Research & Development) | Open-market purchase | +20,000 | $2.53 | $50,600 |
| Feb 1, 2024 | Lin Patrick Officer (Chief Business - Strategy Off) | Open-market purchase | +1,500 | $2.40 | $3,600 |
| Jan 31, 2024 | Lin Patrick Officer (Chief Business - Strategy Off) | Open-market purchase | +2,500 | $2.37 | $5,925 |
| Jan 30, 2024 | George K. Ng Director, Officer (Chief Executive Officer) | Open-market purchase | +10,000 | $2.70 | $27,000 |
| Jan 30, 2024 | Justin W. Yorke Director | Open-market purchase | +8,000 | $2.69 | $21,520 |
| Jan 1, 2024 | David Young Director, Officer (Pres. Research & Development) | Option exercise | +1,675 | — | — |
| Jan 1, 2024 | Stanker James H Officer (Chief Financial Officer) | Option exercise | +1,675 | — | — |
| Jan 1, 2024 | Lin Patrick Officer (Chief Business - Strategy Off) | Option exercise | +1,675 | — | — |
| Jan 1, 2024 | Bigora Sian Officer (Chief Development Officer) | Option exercise | +1,675 | — | — |
| Jan 1, 2024 | Guy Wendy Officer (Chief Administrative Officer) | Option exercise | +1,675 | — | — |
| Jan 1, 2024 | David Young Director, Officer (Pres. Research & Development) | Shares withheld for tax | −518 | $2.79 | $1,445 |
| Jan 1, 2024 | Stanker James H Officer (Chief Financial Officer) | Shares withheld for tax | −518 | $2.79 | $1,445 |
| Jan 1, 2024 | Lin Patrick Officer (Chief Business - Strategy Off) | Shares withheld for tax | −539 | $2.79 | $1,504 |
| Jan 1, 2024 | Bigora Sian Officer (Chief Development Officer) | Shares withheld for tax | −368 | $2.79 | $1,027 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.